Bull Market Presents Opportunities for Growth and Dividend Stocks Like Novavax and Pfizer
-
The S&P 500 is in a bull market, presenting opportunities for investors to benefit by investing in growth stocks.
-
Novavax is a risky but potential high growth investment option, with a combined flu/COVID-19 vaccine in development that could drive future revenue.
-
Pfizer faces some patent expirations but has several growth drivers that could offset revenue declines, along with strategic acquisitions.
-
Pfizer offers a solid dividend and is very cheap right now, though its growth prospects are more limited than Novavax.
-
For risk-averse investors, Pfizer is the better buy, while more aggressive investors may favor the higher growth potential of Novavax.